Geode Capital Management
CTOR

Geode Capital Management’s Citius Oncology CTOR Stock Holding History

Geode Capital Management’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164K Buy
264,733
+44,686
+20% +$44.9K ﹤0.01% 3987
2025
Q4 		$220K Buy
220,047
+52,875
+32% +$75.8K ﹤0.01% 3868
2025
Q3 		$339K Buy
167,172
+109,875
+192% +$238K ﹤0.01% 3749
2025
Q2 		$249K Buy
57,297
+36,758
+179% +$42.9K ﹤0.01% 3800
2025
Q1 		$19.1K Buy
20,539
+7,888
+62% +$8.45K ﹤0.01% 4356
2024
Q4 		$14.5K Buy
+12,651
New +$14.2K ﹤0.01% 4408

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Geode Capital Management's CTOR Position: Q1 2026 in Review

Geode Capital Management increased its Citius Oncology (CTOR) stake by 20% in Q1 2026, buying an estimated $44.9K and bringing the position to 264,733 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #3987.

Geode Capital Management first reported a position in CTOR in Q4 2024 and has held it in 6 quarters since. The position peaked at $339K in Q3 2025. 14 funds tracked by Wall St. Rank hold CTOR as of Q1 2026.

  • Geode Capital Management held 264,733 shares of Citius Oncology worth $164K as of Q1 2026.
  • Geode Capital Management bought 44,686 Citius Oncology shares in Q1 2026, an estimated $44.9K.
  • Citius Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3987 holding.
  • Geode Capital Management first reported a position in Citius Oncology in Q4 2024 and has held it in 6 quarters since.
  • Geode Capital Management's Citius Oncology position peaked at $339K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.